| |
TMC114 Access & Reimbursement Hotline
|
| |
| |
Tibotec has made available a TMC-114 hotline for patients who have questions about access and reimbursement or who lack reimbursement:
1-866-836-0114
As you probably know TMC-114 is a new protease inhibitor approved by the FDA and available in the pharmacy in June 2006. Clearly, this drug can be very helpful for patients with drug resistance and limited therapy options who are putting together a new regimen. Studies show it to be very potent and effective for many patients with extensive protease inhibitor experience and resistance. The most recent update on efficacy and safety was the 48 week study results reported in Toronto in August at the Intl AIDS Conference. At week 24, 70% of highly treatment-experienced patients in the phase III POWER Studies achieved a 1 log or more reduction in viral load, and at week 48 it was 61%. At week 24 45% of patients had <50 copies/ml, and this remained at 46% at week 48, and this compared with 10-12% of patients who achieved <50 copies/ml in the comparator arm in the study, patients who received a regimen without TMC-114. regimen.
Here are maps made available by Tibotec showing the States in which Medicaid & ADAP coverage are provided for TMC114. Most States are providing access and reimbursement for TMC114.
|
|
| |
| |
|
|
|
